Cutaneous Oncology![]() |
Find a Doctor![]() Ahmad Tarhini, MD, PhDDirector, Cutaneous Clinical and Translational Research Specialty: Medical OncologyProgram: Cutaneous Oncology
Overview
Cancer Focus: Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Skin Cancer (Nonmelanoma), Squamous Cell Carcinoma Ahmad Tarhini, MD, PhD is an internationally recognized physician and leading researcher in Melanoma, Skin Cancers and Immuno-Oncology. Dr. Tarhini is a Tenured Senior Member in the Moffitt Cancer Center and Research Institute Departments of Cutaneous Oncology and Immunology. Dr. Tarhini also serves as the Director of Cutaneous Clinical and Translational Research and leader of the Neoadjuvant and Adjuvant Translational Science Program. He is Professor of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Dr Tarhini also serves as Chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN) and Chair, ORIEN ImmunoOncology Research Subcommittee. Dr. Tarhini obtained his MD from the Lithuanian University of Health Sciences (LSMU) and his PhD in Clinical and Translational Science from the University of Pittsburgh School of Medicine (UPSOM). He also obtained a Master of Science in Clinical Research from UPSOM and Bachelor of Science from the American University of Beirut. Dr. Tarhini completed an Internal Medicine Residency and a Hematology and Oncology Fellowship at the University of Pittsburgh Medical Center. Following his Fellowship, Dr. Tarhini joined the faculty of the University of Pittsburgh School of Medicine at the rank of Assistant Professor, was promoted to Associate Professor and eventually achieved tenure. Dr. Tarhini then joined the Cleveland Clinic in Cleveland, OH as Director of the Melanoma and Skin Cancer Program and Director of the Center for ImmunoOncology Research. While at the Cleveland Clinic, he also was Professor of Medicine at Case Western Reserve University and served as the principal investigator of the ETCTN grant at Case Comprehensive Cancer Center. Dr. Tarhini has led multiple clinical trials and biomarker studies funded through the NIH and other mechanisms in the field of ImmunoOncology and has investigated the role of promising biomarkers in relation to disease risk and clinical benefits of immunotherapy in the melanoma adjuvant, neoadjuvant, and advanced disease settings. His original work on immunotherapy of melanoma and biomarkers of disease prognosis and therapeutic benefit has been published in high-impact, peer-reviewed journals and presented at leading national/international meetings. He serves as a chair/co-chair on several NCI cooperative group trials, including U.S. Intergroup clinical trials E1609, S1404, EA6141, E3612, E3611, NCI8628, NCI10061 and EA6194. He is recipient of the University of Pittsburgh Cancer Institute Junior Scholar Award in Clinical Research, the Easten Cooperative Oncology Group Research and Education Foundation Young Investigator Award and the H. Lee Moffitt Cancer Center and Research Institute Top Publication Award. Board certified in medical oncology, Dr. Tarhini’s clinical interests include melanoma (cutaneous, uveal and mucosal) and other skin cancers. Education & TrainingFellowship:
Residency:
Medical School:
Participating Trials
CLINICAL TRIAL 20494
CLINICAL TRIAL 20794
CLINICAL TRIAL 21239
CLINICAL TRIAL 20313
CLINICAL TRIAL 21344
CLINICAL TRIAL 21080
CLINICAL TRIAL 20955
CLINICAL TRIAL 21741
If you believe you are eligible for one of these trials or studies, please call
Publications
Grants
Title: Predictors of Immunotherapeutic Benefits in Patients with Advanced Solid Tumors Treated with Immune Checkpoint Inhibitors
Patient Comments
Overall Satisfaction
4.8
158 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question. Comments ()Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy. We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic. Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months. Learn more about our patient commentsProvider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
|